〔Abstract〕 In the past decades, the clinical physicians’ awareness of differentiated thyroid cancer has been constantly improved, which is closely related to the continuous improvement of image examination, among which positron emission tomography/computed tomography (PET/CT) has attracted more and more attention these years. ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) is the PET imaging tracer which is the most commonly used in clinical oncology, and it is also the most common PET imaging agent used in thyroid tumors. Beyon ¹⁸F-FDG, other tracers can also be used for PET imaging of thyroid tumors, such as ¹⁸F-tetrafluoroborate (¹⁸F-TFB), ⁶⁸Gaprostate-specific membrane antigen (⁶⁸Ga-PSMA) and radionuclide labeled fibroblast activation protein inhibitor (FAPI). This review will summarize the role of PET/CT in the diagnosis and treatment of DTC patients from the perspective of clinical application.